<div><div>Vědci z Ústavu organické chemie a biochemie AV ČR (ÚOCHB) vyvinuli průlomovou technologii pro efektivní vývoj aptamerů. Nová metoda propojuje několik biochemických a bioinformatických kroků a otevírá cestu k novým diagnostickým a terapeutickým aplikacím. Mezi ně patří například nositelné senzory schopné v reálném čase sledovat hladiny vybraných biomarkerů v těle a včas upozornit na blížící se zdravotní komplikace. Výsledky zveřejnil časopis Nature Communications.</div></div><div>Aptamery jsou krátké řetězce DNA nebo RNA, které dokážou velmi přesně rozeznat a navázat konkrétní cílovou molekulu. Podobně jako protilátky je lze využít k detekci nebo ovlivnění funkce těchto molekul. Na rozdíl od protilátek jsou však mnohem stabilnější, lze je vyrábět synteticky a přesně chemicky upravovat podle požadovaných vlastností. Díky tomu mohou získat vlastnosti, kterých nelze u protilátek dosáhnout.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/UOCHB_Nova_technologie_inovuje_vyvoj_aptameru_syntetickych_alternativ_protilatek_2_81e99b9900.jpg" alt="ÚOCHB: Nová technologie inovuje vývoj aptamerů, syntetických alternativ protilátek: Chemicky upravený DNA aptamer navázaný na cílový protein." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_UOCHB_Nova_technologie_inovuje_vyvoj_aptameru_syntetickych_alternativ_protilatek_2_81e99b9900.jpg 228w," sizes="100vw" width="1343" height="916">S rostoucí poptávkou po přesných a rychlých diagnostických nástrojích jsou aptamery v mnoha případech vhodnější než samotné protilátky. Jejich vývojový proces je však experimentálně a časově náročný a vyžaduje experty z několika vědních oborů. Tým vědců z ÚOCHB vedený dr. Markem Ondrušem a <a target="_blank" rel="noopener noreferrer" href="https://hocek.group.uochb.cz/">prof. Michalem Hockem</a> nyní vyvinul technologii, která celý vývojový proces výrazně zkracuje.„Vývoj aptameru často připomíná hledání jehly v kupce sena. Ve směsi bilionů různých DNA sekvencí se snažíme najít jedinou, která se silně a specificky váže na cílovou molekulu. Náš nový přístup umožňuje nejdřív nalézt ‚aptamerové rodiny‘ – stovky sekvencí s jistou podobností a následně identifikovat člena rodiny, který vykazuje nejlepší experimentální vlastnosti. Tento prvek přispívá ke zkrácení vývoje z několika měsíců na dny,“ říká Marek Ondruš.<blockquote>Video: <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/watch?v=-aoGvOKqORo">Nová technologie inovuje vývoj aptamerů, syntetických alternativ protilátek&nbsp;</a></blockquote>Výzkumníci zároveň rozšířili možnosti využití aptamerů. Jejich stavební bloky totiž chemicky upravují – připojují k nim nové funkční skupiny, které můžeme přirozeně najít například v aminokyselinách. Takto vzniklé molekuly kombinují výhody DNA i protilátek: pořadí jednotlivých stavebních bloků je dané pořadím písmen v DNA a díky rozmanitosti připojených chemických modifikací se výrazně rozšiřují možnosti aptameru rozpoznávat biologicky významné cíle a napodobovat interakce typické pro proteiny, které jsou základem mnoha biologických procesů.&nbsp;Potenciál nové metody ukázali vědci na lidském inzulinovém receptoru, klíčovém proteinu zapojeném do regulace hladiny cukru v krvi. Vyvinuli aptamer, který se na receptor specificky váže, a pomocí kryoelektronové mikroskopie detailně popsali molekulární mechanismus vzájemné vazby.„Ukázali jsme, že chemicky zavedené funkční skupiny mají zásadní význam nejen pro rozpoznání a vytvoření komplexu aptameru s proteinem, ale také pro stabilizaci samotné struktury DNA aptameru. Naše výsledky poskytují nový pohled na to, jak lze pomocí chemicky upravených nukleových kyselin napodobovat vlastnosti proteinů,“ shrnuje Marek Ondruš.Technologie by v budoucnu mohla doplnit nebo v některých aplikacích dokonce nahradit diagnostické nástroje založené na protilátkách. Výzkumníci spolupracují na dalším rozvoji technologie se společností <a target="_blank" rel="noopener noreferrer" href="http://iocbtech.cz/">IOCB Tech</a>, která pomáhá přetavit objevy z ÚOCHB do praxe.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/UOCHB_Nova_technologie_inovuje_vyvoj_aptameru_syntetickych_alternativ_protilatek_9694c21671.jpg" alt="ÚOCHB/Tomáš Belloň: Nová technologie inovuje vývoj aptamerů, syntetických alternativ protilátek: Dr. Marek Ondruš, první autor studie, a prof. Michal Hocek, vedoucí vědecké skupiny Bioorganická a medicinální chemie nukleových kyselin, ÚOCHB" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_UOCHB_Nova_technologie_inovuje_vyvoj_aptameru_syntetickych_alternativ_protilatek_9694c21671.jpg 234w," sizes="100vw" width="2000" height="1335"><blockquote><h4>Původní článek</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://www.nature.com/articles/s41467-026-73676-y">Expedient single-round selection of hyper-modified aptamer targeting insulin receptor from over-represented dually nucleobase-modified DNA libraries</a></h4>Pablo Alberto Franco-Urquijo, Marek Ondruš, Jaroslav Kurfürst, Jana Škerlová, Irena Selicharová, Lucie Mužíková Čechová, Hana Šváchová, Alena Semerádtová, Anatolij Filimoněnko, Adéla Fejfarová, Jiří Homola, Tomáš Kouba &amp; Michal HocekNat. Commun., 2026<a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1038/s41467-026-73676-y">https://doi.org/10.1038/s41467-026-73676-y</a>&nbsp;<h6>licencováno pod <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote><h4>Abstrakt</h4>Objev funkčních nukleových kyselin z knihoven náhodných sekvencí se obvykle opírá o několik časově náročných iterativních kol in vitro selekce s nízkou mírou úspěšnosti. V této práci představujeme strategii selekce v jediném kole, která umožňuje rychlý screening několika nadreprezentovaných DNA knihoven s modifikovanými nukleobázemi a různých selekčních podmínek a dokáže identifikovat modifikované aptamery s vysokou afinitou. Dvojitá separace následovaná amplifikací eluovaných sekvencí, analýzou NGS a klastrováním umožňuje rychlou identifikaci kandidátních aptamerů. Screening modifikovaných DNA knihoven obsahujících modifikované adeninové a uracilové nukleotidy nesoucí hydrofobní aromatické fenylové a indolové skupiny vedl k vývoji aptameru, který se váže na lidský inzulinový receptor se subnanomolární afinitou a mimořádnou specificitou. Struktura stanovená kryoelektronovou mikroskopií odhaluje význam každé aromatické modifikace, a to buď při stabilizaci sekundární struktury, nebo při zprostředkování interakcí s povrchem proteinu. Tento přístup překonává hlavní omezení selekce aptamerů a má potenciál pro vysokokapacitní screening i urychlení vývoje aptamerů nové generace pro diagnostické nebo terapeutické aplikace.</div>

Nová technologie inovuje vývoj aptamerů, syntetických alternativ protilátek

<div><div>Nadace Experientia podpoří tříletým start-up grantem vycházející hvězdu organické chemie Petru Vojáčkovou. Mladí talentovaní vědci Tereza Edlová a Ladislav Prener vycestují na zahraniční stáže.</div></div><div><div><a target="_blank" rel="noopener noreferrer" href="https://www.experientia.cz/start-up-granty/vyvijime-nove-strategie-pro-stavbu-molekul">Petra Vojáčková </a>z <a target="_blank" rel="noopener noreferrer" href="https://www.uni-muenster.de/en/">University of Münster</a>&nbsp;založí svoji výzkumnou skupinu na <a target="_blank" rel="noopener noreferrer" href="https://www.muni.cz/">Masarykově univerzitě</a> v Brně, kterou od ledna 2027 podpoří start-up grant Nadace Experientia ve výši 6 600 000 Kč. Se svým týmem bude vyvíjet nové strategie pro stavbu molekul tak, aby vznikala výhradně jejich žádoucí zrcadlová podoba.<a target="_blank" rel="noopener noreferrer" href="https://www.experientia.cz/zahranicni-staze/chceme-zefektivnit-vyzkum-v-oblasti-novych-materialu-i-leciv">Tereza Edlová </a>z <a target="_blank" rel="noopener noreferrer" href="https://www.vscht.cz">VŠCHT Praha</a> díky stipendiu ve výši 1 260 000 Kč vycestuje na roční stáž na britskou <a target="_blank" rel="noopener noreferrer" href="https://www.manchester.ac.uk">University of Manchester</a> do skupiny prof. Igora Larrosy, kde se bude věnovat projektu, který může zefektivnit výzkum v oblasti materiálů i léčiv.<a target="_blank" rel="noopener noreferrer" href="https://www.experientia.cz/zahranicni-staze/nase-metoda-by-mohla-urychlit-vyvoj-novych-leku">Ladislav Prener </a>z <a target="_blank" rel="noopener noreferrer" href="https://www.uochb.cz/cs">ÚOCHB AV ČR</a> získal stipendium ve výši 1 200 000 Kč a zamíří na německou <a target="_blank" rel="noopener noreferrer" href="https://www.rwth-aachen.de/cms/~a/root/?lidx=1">RWTH Aachen University</a> do skupiny prof. Leonoriho. Na své roční stáži bude vyvíjet metodu, která by mohla urychlit vývoj nových léků.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Nadace_Experientia_Nadace_Experientia_zna_drzitelku_start_up_grantu_a_stipendisty_pro_rok_2026_c96fdf9a4f.jpg" alt="Nadace Experientia: Nadace Experientia zná držitelku start-up grantu a stipendisty pro rok 2026" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Nadace_Experientia_Nadace_Experientia_zna_drzitelku_start_up_grantu_a_stipendisty_pro_rok_2026_c96fdf9a4f.jpg 234w," sizes="100vw" width="600" height="400"><blockquote>Nadace Experientia od roku 2012 podpořila už 27 nadějných mladých vědkyň a vědců, kteří díky stipendiu dostali šanci vycestovat na roční stáž na špičková zahraniční vědecká pracoviště. Díky programu start-up grantů si mohlo dalších 6 mladých vědkyň a vědců založit po návratu ze zahraničí vlastní výzkumnou skupinu v ČR. Celkem už na podporu mladých vědkyň a vědců vyčlenila Nadace Experientia více než 73 milionů korun.</blockquote></div></div>

Nadace Experientia zná držitelku start-up grantu a stipendisty pro rok 2026

V týdnu od 29. června na Vás čekají v oblasti kapalné fáze a především HPLC a LC/MS následující webináře.<blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://www.lcms.cz/webinars">👉 DETAILY A REGISTRACE V SEKCI WEBINÁŘE</a></h4></blockquote><blockquote>👉 Vyhledávejte a filtrujte v největší globální databázi s více než 5 500 GC, HPLC, MS a spektroskopickými webináři.</blockquote><h5>1. Thermo Fisher Scientific: Insights from an IC Specialist: To Be Suppressed or Not Suppressed?</h5><ul><li>Út, 30.6.2026 09:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6310">Registrace</a></li></ul>Zjistěte, jak technologie supresorů ovlivňuje citlivost, selektivitu, spolehlivost i nároky na údržbu v iontové chromatografii. Webinář představí výhody i omezení potlačené a nepotlačené vodivostní detekce a nabídne praktické tipy pro řešení běžných problémů.<h5>2. SCIEX: Advancing Proteomics with ZenoTOF: From Single-Cell Analysis to Plasma Biomarker Discovery</h5><ul><li>Út, 30.6.2026 11:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6311">Registrace</a></li></ul>Objevte možnosti hmotnostní spektrometrie ZenoTOF pro proteomiku jednotlivých buněk i analýzu plazmatických biomarkerů. Přednáška ukáže, jak vysoké rozlišení a citlivost urychlují biologický výzkum a objevování nových biomarkerů.<h5>3. Agilent Technologies: Measuring Diverse Samples with UV/VIS Spectrometers and Integrating Spheres</h5><ul><li>Út, 30.6.2026 20:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6052">Registrace</a></li></ul>Naučte se správně měřit difúzní transmitanci a reflektanci pomocí UV/VIS spektrometrů s integrační koulí. Webinář představí praktické využití systému Cary 60 při analýze široké škály materiálů.<h5>4. Waters Corporation: Informatics Series #33: Tips, Tricks and Best Practices</h5><ul><li>Čt, 2.7.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6315">Registrace</a></li></ul>Interaktivní lekce zaměřená na software Empower představí užitečné funkce, klávesové zkratky a osvědčené pracovní postupy, které pomohou zrychlit každodenní práci a zvýšit efektivitu zpracování chromatografických dat.<h5>5. Waters Corporation: Unlocking Therapeutic Peptide Characterisation (GLP-1RAs) with Cyclic IMS</h5><ul><li>Čt, 2.7.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6313">Registrace</a></li></ul>Zjistěte, jak cyklická iontová mobilita rozšiřuje možnosti charakterizace terapeutických peptidů a analogů GLP-1. Webinář ukáže přínosy této technologie pro vývoj léčiv, kontrolu kvality i regulatorní dokumentaci.<h5>6. Agilent Technologies: Spectral Flow Cytometry Masterclass – Session 1</h5><ul><li>Pá, 3.7.2026 07:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.cz/webinar/6316">Registrace</a></li></ul>První část odborné série představí principy spektrální průtokové cytometrie, návrh experimentů a praktické aplikace v imunologii, onkologii i výzkumu vakcín.

Webináře LabRulezLCMS týden 27/2026

Webináře

Popularizace

Věda a výzkum

Video

Článek

Podporujeme mladé vědkyně a vědce z oboru organické, bioorganické a medicinální chemie na zahraničních stážích i zde v ČR díky tzv. start-up grantům Nadace Experientia.

Nadace Experientia

ÚOCHB AV ČR je přední mezinárodně uznávaná vědecká instituce, jejímž hlavním posláním je základní výzkum v oblasti chemické biologie a medicinální chemie, organické a materiálové chemie, chemie přírodních látek, biochemie a molekulární biologie, fyzikální chemie, teoretické chemie a analytické chemie.

Ústav organické chemie a biochemie AV ČR

Vše ze světa analytické chemie na jednom místě. Propojujeme lidi při řešení jejich problémů. U nás naleznete všechny potřebné informace snadno, rychle a přehledně. Přestaňte hledat a začněte nacházet.

LabRulez

Separation Science

Agilent Technologies

Bruker

Thermo Fisher Scientific

Shimadzu Corporation

SCIEX

Waters Corporation

<h3>Solving Problems That Matter - a Waters webinar series featuring USP speakers</h3><h4>Episode 9: Nitrosamines</h4>When present in pharmaceutical products, nitrosamine impurities - a probable carcinogen - can disrupt drug supply chains and lead to shortages resulting from product recalls and withdrawals.Join our panelists Naiffer Romero from the USP and Marian Twohig from Waters Corporation as they address analytical challenges in the detection and control of nitrosamines and Nitrosamine Drug-Substance Related Impurities (NDSRIs).Key learning objectives:<ul><li>Understand the current analytical challenges associated with the detection and control of nitrosamine impurities. Explore fit-for-purpose and compliant-ready LC-MS-MS solutions for the cGMP laboratory.</li></ul>Who should attend:<ul><li>Pharmaceutical scientists involved with the detection and control of nitrosamines impurities</li></ul><blockquote>Presenter: Naiffer Romero, MSc, MPH (Principal Scientist - Scientific Affairs, US Pharmacopeia)</blockquote><blockquote>Naiffer has more than 20 years of pharmaceutical industry experience. In his 13+ years tenure with USP, he has served several roles: Lead scientist in the dosage form performance laboratory, reference standard development team, Manager in charge of LATAM Compendial engagement and education, responsible for stakeholders and national regulatory bodies engagement. Naiffer is also a certified USP Education instructor. Most recently, Naiffer joined USP's Scientific Affairs performance cell, where he leads scientific outreach and engagement for LATAM &amp; U.S. on key national health priority topics. His combined pharmaceutical expertise includes Analytical Development, salt and polymorph selection, Development of dissolution methods, IVIVC modeling, and impurity analytical strategy. Naiffer also serves as a member of USP's Nitrosamine Steering Committee and community host to 'Nitrosamine Exchange,' a knowledge community in All-things Nitrosamine. Naiffer also liaises technical discussion on pharmacopeial collaboration, including international meetings of World Pharmacopeias (part of WHO).</blockquote><blockquote>Presenter: Marian Twohig, Ph.D. (Consultant Scientist, Waters Corporation)</blockquote><blockquote>Marian has over 20 years of experience supporting quantitative and qualitative applications in the pharmaceutical, food and environmental and materials science industries. She works as a Consultant Scientist for Waters Corporation where she has previously held several Senior Scientist positions. Currently, the focus of Marian’s work is in the development of quantitative analytical methods to meet the needs of the pharmaceutical industry. She is particularly interested in chromatographic separations and the application of combining low- and high-resolution mass spectral data with other chemical information for identification of unknown chemical entities. Marian holds a Ph.D. in Analytical Chemistry from Munster Technological University, Cork, Ireland.</blockquote><blockquote>Moderator: Isabelle Vu Trieu (Pharmaceutical Market Development Manager, Americas, Waters Corporation)</blockquote><blockquote>Isabelle is a business development professional dedicated to delivering benefits to analytical scientists in the life sciences industry. With over 20 years of experience in providing chromatography and mass spectrometry solutions, Isabelle is particularly interested in helping pharmaceutical scientists achieve the data quality and integrity needed to drive decisions for drug quality, safety and efficacy. Isabelle joined Waters in 2009 and currently manages the development of the pharmaceutical market in the Americas. She holds Masters’ degrees in Chemistry from Columbia University and the University Claude Bernard in Lyon, France as well as a Chemical Engineering degree from Ecole Supérieure de Chimie Physique Electronique in Lyon, France.</blockquote>

Waters Corporation: Solving Problems That Matter - a Waters webinar series featuring USP speakers

Nitrosamines

This webinar will address analytical challenges in the detection and control of nitrosamines and Nitrosamine Drug-Substance Related Impurities (NDSRIs).

<h4>Virtual event: Pharma conclave series 2024</h4>SCIEX offers the platform for the experts to take the stage and drive technological progressWelcome to Pharma conclave series 2024 – where our customers’ expertise meets innovation, transforming your knowledge and empowering you to revolutionize your work processes. Join us in discovering techniques that will enhance your skills to accelerate your daily operations in the development of new drugs.From the research of new markers to the drug development moving into non and GLP bioanalysis. Confidently plan your next lab expansion with the knowledge gained from industry leaders and pioneers.<ul><li>May 16 Event 1: Pharma omics</li><li>September 17 Event 2: Impurities</li><li>October 23-24 Event 3: Pharma</li></ul>10:00 a.m.–12:00 p.m. CET<h3>Event 3: Pharma</h3>The pharma connectionFrom discovery to QA/QC. All the process to bring a new treatment to the patients is following a path to connect the different stages until the magic happens.Join to see how the scientists are generating the needed tricks to connect the initial though with the final formulation.<h3>Day 1</h3><h5>10:00 - 10:30 - Metabolomics screening kits for use in clinical trials</h5><ul><li>Heike Wiese, Nuvisan</li></ul><h5>10:30 – 11:00&nbsp;- Sphingolipid biomarkers in neurodegenerative drug development</h5><ul><li>Jose Carlos Gonzalez, AMSbiopharma</li></ul><h5>11:00 – 11:30 - Parallel setup of a series of micro LC methods, coupled with the low-resolution mass spec (API7500) for &nbsp;TG2 inhibitors</h5><ul><li>Davide Massari and Chiara Olmi, ERBC Group</li></ul><h5>11:30 – 12:00&nbsp;- PFAS analysis and mass spectrometry: Beyond environmental, food and packaging. What about cosmetic and pharmaceutical products?</h5><ul><li>Emiliano De Dominicis, Merieux</li></ul><blockquote>Presenter: Bruno Manadas, PhD</blockquote><blockquote>Dr Manadas is a prominent Cell Biology researcher at CNC-UC since 2017. With expertise in biochemistry, psychology, and biotechnology, he's authored 130+ publications and led multiple projects. As head of CNC's Mass Spectrometry node and Associate Editor for Frontiers, he's contributed significantly to neuroscience and psychiatry. Bruno's research focuses on cell biology mechanisms, translational biomarker research, and MS-based approaches for studying protein oxidation. He played a pivotal role in establishing the hospital biobank and teaches at the Portuguese Catholic University.</blockquote><blockquote>Presenter: Dorte Bekker-Jensen</blockquote><blockquote>Dorte is heading the Applications Development team in Proteomics Research at Evosep. She has long-term experience within proteomics and has focused on technology development by developing simple and automated workflows for high-throughput applications.</blockquote><blockquote>Presenter: Stefan Ledinger</blockquote><blockquote>Stefan has 20 years of experience in the life sciences and diagnostic industries. For the last dozen years, he has been serving various functions within biocrates life sciences ag. Most recently, he has been responsible for the market development for metabolomics solutions in the pharmaceutical and biotech industries. He currently serves as Global Head of Sales. Stefan holds degrees in business administration and bioengineering, combining commercial know-how with a passion for science.</blockquote><blockquote>Presenter: Markus Langsdorf</blockquote><blockquote>Markus has 14 years of experience in life sciences industries. As he joined biocrates in 2010, he worked for 11 years as application support specialist for biocrates’ metabolomics profiling solutions. 3 years ago he changed his position withing the company to his new function as product manager. Markus studied chemistry and graduated with a PhD in Analytical Chemistry.</blockquote>

Pharma conclave series 2024: Pharma (Day1)

From discovery to QA/QC. The process to bring a new treatment to the patients.

<h4>Virtual event: Pharma conclave series 2024</h4>SCIEX offers the platform for the experts to take the stage and drive technological progressWelcome to Pharma conclave series 2024 – where our customers’ expertise meets innovation, transforming your knowledge and empowering you to revolutionize your work processes. Join us in discovering techniques that will enhance your skills to accelerate your daily operations in the development of new drugs.From the research of new markers to the drug development moving into non and GLP bioanalysis. Confidently plan your next lab expansion with the knowledge gained from industry leaders and pioneers.<ul><li>May 16 Event 1: Pharma omics</li><li>September 17 Event 2: Impurities</li><li>October 23-24 Event 3: Pharma</li></ul>10:00 a.m.–12:00 p.m. CET<h3>Event 3: Pharma</h3>The pharma connectionFrom discovery to QA/QC. All the process to bring a new treatment to the patients is following a path to connect the different stages until the magic happens.Join to see how the scientists are generating the needed tricks to connect the initial though with the final formulation.<h3>Day 2</h3><h5>10:00 - 10:30&nbsp;- Metabolomics: From target engagement to metabolic phenotyping. Applications in drug discovery</h5><ul><li>Filippos Michopoulos, Astrazeneca</li></ul><h5>10:30 - 11:00&nbsp;- Development of an LC-MS Method to Quantify Endogenous Urea in Mouse Plasma and BAL.</h5><ul><li>Benjamin Smith, Cyprotex</li></ul><h5>11:00 - 11:30&nbsp;- Optimization of extraction &amp; LC-MS conditions for the bioanalysis of antibody drug conjugates with diverse chemistries</h5><ul><li>John Perkins, KCAS</li></ul><h5>11:30 - 12:00&nbsp;- Preparation of rodent whole blood and plasma microsamples for LC-MS/MS bioanalysis in toxicology studies</h5><ul><li>Birgitte Støvring, Scantox</li></ul><blockquote>Presenter: Bruno Manadas, PhD</blockquote><blockquote>Dr Manadas is a prominent Cell Biology researcher at CNC-UC since 2017. With expertise in biochemistry, psychology, and biotechnology, he's authored 130+ publications and led multiple projects. As head of CNC's Mass Spectrometry node and Associate Editor for Frontiers, he's contributed significantly to neuroscience and psychiatry. Bruno's research focuses on cell biology mechanisms, translational biomarker research, and MS-based approaches for studying protein oxidation. He played a pivotal role in establishing the hospital biobank and teaches at the Portuguese Catholic University.</blockquote><blockquote>Presenter: Dorte Bekker-Jensen</blockquote><blockquote>Dorte is heading the Applications Development team in Proteomics Research at Evosep. She has long-term experience within proteomics and has focused on technology development by developing simple and automated workflows for high-throughput applications.</blockquote><blockquote>Presenter: Stefan Ledinger</blockquote><blockquote>Stefan has 20 years of experience in the life sciences and diagnostic industries. For the last dozen years, he has been serving various functions within biocrates life sciences ag. Most recently, he has been responsible for the market development for metabolomics solutions in the pharmaceutical and biotech industries. He currently serves as Global Head of Sales. Stefan holds degrees in business administration and bioengineering, combining commercial know-how with a passion for science.</blockquote><blockquote>Presenter: Markus Langsdorf</blockquote><blockquote>Markus has 14 years of experience in life sciences industries. As he joined biocrates in 2010, he worked for 11 years as application support specialist for biocrates’ metabolomics profiling solutions. 3 years ago he changed his position withing the company to his new function as product manager. Markus studied chemistry and graduated with a PhD in Analytical Chemistry.</blockquote>

Pharma conclave series 2024: Pharma (Day 2)

This webinar will guide you through optimizing your Q-TOF for superior data quality by selecting the most suitable tune mode for your samples.You will learn about the different optimisation workflows available within MassHunter Acquisition, including how to optimise Multiple Reaction Monitoring (MRM) methods for new compounds. We will also review key tools for creating and editing worklists, and discuss the benefits of Intelligent Reflex tools, demonstrating how they can be effectively implemented in your workflows.This webinar is designed to enhance your understanding and application of MassHunter Acquisition, ensuring you can achieve optimal performance in your analytical processes.<blockquote>Presenter: Day Powell (Field Application Specialist, Agilent Technologies)Day has worked for Agilent as an Environmental Application Specialist for over a year, before this he worked for United Utilities (UU) as a Technical Specialist responsible for developing new methodologies for both LC/MS and GC/MS applications. Day has worked with PFAS for several years and helped UU to UKAS accredit a novel method for 47 PFAS in drinking water using direct injection to address the latest DWI regulations. Presenter: Jonathan Spencer (Application Specialist, Agilent Technologies)Jonathan studied BSc Natural Sciences at the University of Nottingham and later went on to Sheffield Hallam University to study a MSc in Forensic Science.Following graduation, he spent 2 years as a Confirmatory Analyst in an anti-doping and forensic toxicology lab, before joining Agilent as an LC/MS Applications Scientist. At Agilent, he focuses on small molecule applications using LC/TQ and LC/Q-TOF in fields of like food, forensic and environmental analysis.</blockquote>

Agilent Technologies: MassHunter Masterclass Months

MassHunter Acquisition for LC/TQ and MRM Method Optimisation

This session will provide a comprehensive overview of the various aspects of MassHunter Acquisition for Liquid Chromatography/Triple Quadrupole (LC/TQ) systems.

Measurement of FT4 and FT3 is typically performed by immunoassay, however these can be prone to suffer from interferences and a lack of selectivity. Currently, the accepted gold standard for the measurement of FT4 and FT3 is using equilibrium dialysis (ED) and combined with the use of LC-MS/MS can overcome the issues with immunoassay in the measurement of FT4 and FT3. However, the equilibrium dialysis procedure can be quite time consuming and often being performed overnight.Here, we describe a simple clinical research method to perform ED using a commercially available device followed by sample preparation by solid phase extraction (SPE) and UPLC-MS/MS analysis using the Waters™ ACQUITY™ UPLC and analytically sensitive Xevo™ TQ Absolute Mass Spectrometer for clinical research. Data analysis and review has been simplified with the use of the waters_connect™ with QUAN Review Software. This has allowed for the complete workflow including equilibrium dialysis to be performed within a typical working day.Simplified Equilibrium Dialysis for the UPLC-MS/MS Analysis of Free Testosterone (FT) for Clinical ResearchHistorically, the measurement of free testosterone in human serum has presented a challenge for laboratory scientists, with such a large portion bound and the complexity and time involved in “gold standard” equilibrium dialysis. With a simple, fast, workflow combined with the analytical sensitivity afforded by the Waters Xevo™ TQ Absolute Mass Spectrometer, a newly developed, precise, accurate and selective clinical research method will be presented.<blockquote>Presenter: Robert Wardle (Senior Clinical Scientist, Waters Corporation)Robert Wardle is currently a Senior Scientist employed at Waters Corporation in Wilmslow, UK, performing research and development of applications and products for Clinical Research. His primary area of research is vitamins and in particular vitamin D metabolites, steroid hormones and in-depth knowledge of offline and online automation.Robert joined Waters in 2010 as a Clinical Validation Scientist, playing a key role in verification activities for the MassTrak XE Immunosuppressants kit available in the EU. He moved into his current role as a Senior Scientist in 2013, where he developed clinical research methods for a range of applications including vitamin D metabolites, estrogens, a large panel of steroid hormones and more recently this application on free T4 and free T3.Presenter: Stephen Balloch (Senior Clinical Scientist, Waters Corporation)Stephen Balloch graduated from the University of York (UK) with a Master’s degree in Chemistry, which included a strong focus on analytical chemistry. Subsequently he worked as a laboratory scientist in a GLP compliant research facility, progressing to Study Director. And, since 2010, he has been part of the clinical team at Waters (Wilmslow, UK). His principal focus has been on the development and validation of bioanalytical methods according to CLSI guidelines, with a focus on therapeutic drug monitoring. Additionally, he has supported newborn screening, vitamin and steroid analysis, including this clinical research method for free testosterone</blockquote>

Free Testosterone and Free T3/T4

Simplified Equilibrium Dialysis and SPE Method for the UPLC™-MS/MS Analysis of Free Thyroxine (FT4) and Triiodothyronine (FT3) for Clinical Research.

Join us for an enlightening Digital Classrooms session focused on the pivotal advancements in mass spectrometry (MS) technology and its applications in personalized health monitoring, early disease detection, and critical care management.This session, led by esteemed experts Dr. Naatasha Isahak and Dr. Abhik Banerjee, Zonal Technical Chief of Apollo Diagnostics' East Zone, will uncover how MS is transforming modern healthcare.Explore how MS technology facilitates the quantification of vitamins, hormones, metabolites, and proteins, providing insights into metabolic health, nutritional status, and organ function. Additionally, through real-world case studies, learn how MS is utilized for rapid diagnosis and therapeutic monitoring in acute conditions, such as sepsis and organ failure.Don’t miss this opportunity to understand the technical aspects of MS-based assays, as well as practical considerations for integrating these tools into clinical workflows for enhanced patient outcomes. Whether you are involved in clinical diagnostics or health management, join us to discover the expanding influence of mass spectrometry in today’s healthcare landscape.<h5>Learning Objectives:</h5><ul><li>Delve into the latest advancements in MS technology and its applications in personalized health monitoring, early disease detection, and critical care management.</li><li>Discover how MS quantifies biomarkers like vitamins, hormones, metabolites, and proteins, and its role in assessing metabolic health, nutritional status, and organ function.</li><li>Gain practical insights into seamlessly integrating MS-based assays into clinical workflows, with real-world case studies demonstrating its effectiveness in rapid diagnosis and therapeutic monitoring of acute conditions like sepsis and organ failure.</li><li>Explore a concise overview of Shimadzu's innovative solutions tailored for wellness diagnostics and critical care applications.</li></ul><blockquote>Presenter: Dr. Abhik Banerjee (Zonal Technical Chief, East Zone, Apollo Diagnostics)Dr. Abhik Banerjee is a highly accomplished pathologist with over 11 years of post-MD pathology experience and more than a decade as a Consultant Pathologist. He currently serves as the Zonal Technical Chief for East Zone at Apollo Diagnostics, overseeing the operations of around 30 laboratories in East India. A specialist in laboratory medicine, pathology, and quality control, Dr. Banerjee has spearheaded the establishment of the first LC-MS/MS (Tandem mass spectrometry) setup in Eastern India at Suraksha Diagnostics, Kolkata. He has held leadership roles such as Lab Director and Chief of Quality at Suraksha Diagnostics' COVID-19 Cell, and was the Nodal Officer for the only CAP-accredited medical laboratory in East India. He has contributed to the field with publications in national journals and received the Dx Leadership Award in 2019. Additionally, Dr. Banerjee is a certified lead assessor for CAP audits, has extensive experience with NABL and ISO 15189 audits, and has been an active speaker and reviewer for medical journals.Presenter: Naatasha Isahak (Market Specialist (Clinical and Forensics), Shimadzu (Asia Pacific) Pte Ltd)Naatasha Isahak is a Product Specialist for MALDI and Life Sciences Products from Shimadzu Asia Pacific Pte Ltd. She has received her PhD from the University of Sydney (Chemistry) working on surface initiated polymerisation on silica nanoparticles using RAFT polymerisation and bioorthogonal conjugation of peptides using Native Chemical Ligation. She then spent 5 years working on developing platforms for stem cells and organoids characterization that included working with microfluidic devices and helical polymers. Naatasha joined Shimadzu in 2022 to expand her experiences to MALDI characterization on materials and biological samples.</blockquote>

Shimadzu: Wellness Diagnostics And Critical Care

Wellness Diagnostics And Critical Care

We will uncover how MS is transforming modern healthcare.

<div><div>Therapeutic synthetic oligonucleotides represent unique analytical challenges in late-stage development. To meet the stringent regulatory requirements, highly specific and sensitive methods such as liquid chromatography-mass spectrometry (LC/MS) must be used. However, neither chromatography nor mass spectrometry data systems have the capabilities, both in function and in data integrity, for the typical QC analyst end user to run a highly complex method such as purity, assay, and impurity profiling for therapeutic oligos such as anti-sense oligonucleotides.In this presentation, we present a paradigm shift in software with Oligo Analysis Accelerator for OpenLab CDS. This application streamlines the analytical workflow by using a fit-for-purpose user interface while leveraging existing data integrity and compliance architecture within OpenLab CDS.<h4>By attending this webinar, you will:</h4><ul><li>Understand the fundamentals of ion-pair reversed-phase LC/MS for oligonucleotides</li><li>Discover how a single quadrupole detector is used for impurity profiling of anti-sense oligonucleotides</li><li>Learn how fit-for-purpose software for LC/MS analysis in QC lot release can save time and enhance quality</li></ul><h5>Who should attend</h5><ul><li>Analytical chemists interested in cutting-edge software for large molecule late-stage development</li><li>Analytical research and development labs interested in developing robust methods for single-stranded oligo therapeutics</li><li>Process scientists who rely on in-process control purity results to optimize synthesis and purification for oligos</li><li>Quality assurance and quality control personnel supporting oligo testing labs</li></ul><blockquote>Presenter: Brian Rivera (Software Product Manager, Agilent Technologies)Brian Rivera is a software product manager at Agilent Technologies with 20 years of experience in HPLC analysis of large molecules.</blockquote></div></div>

Separation Sciences: Boost Efficiency in Oligonucleotide QC with Software Designed for the Job

Boost Efficiency in Oligonucleotide QC with Software Designed for the Job

In this presentation, we present a paradigm shift in software with Oligo Analysis Accelerator for OpenLab CDS.

Oligonucleotide QC with Software Designed for the Job

In this webinar, Dr Stuart Best, Deputy Director, Drug Metabolism and Pharmacokinetics (DMPK), Sygnature Ltd, will provide an overview of analytical approaches in Discovery Bioanalysis CNS measurement, to deliver more information from lower sample volume and align with the 3R principles.Drug discovery programs that target the Central Nervous System require bioanalytical measurement of test compounds and neurotransmitter concentrations to establish a pharmacokinetic-pharmacodynamic (PK-PD) relationship. Bioanalytical assessment of unbound compounds in blood, brain tissue, and cerebrospinal fluid describes its distribution for the systemic circulation into the CNS. The inherently high sensitivity and specificity of LC-Triple Quadrupole Mass Spectrometry enables low level detection in small sample volumes, allowing serial sampling from single animals, reducing animal use and inter-animal variability, supporting the 3Rs principles (replacement, reduction, refinement)The bioanalysis of neurotransmitters such acetylcholine and monoamines, is challenging due to low molecular weight, high polarity, instability, and low endogenous concentrations. At Sygnature, the in vivo Pharmacology team employ microdialysis to permit assessment of neurotransmitter changes in specific brain regions. The low endogenous concentrations in brain regions and collection through dialysis probe into artificial CSF lowers further quantitation limits for neurotransmitter detection and lead to the requirements for highly sensitive and specific analytical approaches.This presentation will describe the above approached to CNS measurement and how LC-Triple Quadrupole Mass Spectrometry enables Sygnature scientists to align to the 3R principles and maximize data output from small samples and relate test compound concentrations to neurotransmitter changes. Truly, achieving on the concept of ‘More from Less’ Stuart will also present further refinement models for assessing test compound impact on acetylcholine and enabling more physiologically relevant measurements.<h4>Key Learning Objectives:</h4><ul><li>Understand the challenges as CNS measurements of test compounds and neurotransmitter concentrations to establish PK-PD relationships</li><li>Explore the complexities of neurotransmitter bioanalysis in discovery DMPK due to low concentrations and instability</li><li>Learn the roles of LC-Triple Quadrupole Mass Spectrometry enabling sensitive detection in small samples and alignment to the 3Rs (replacement, reduction, refinement) principles</li></ul><div><blockquote>Presenter: Dr Stuart Best (Deputy Director, DMPK, Sygnature Ltd)Dr Best's expertise spans regulated and discovery bioanalysis and discovery DMPK, from supporting DMPK screening (solubility, log D, metabolic stability, permeability, plasma protein binding, etc) through in vivo assessment of compounds to more detailed profiling to support candidate nomination and human dose prediction, including the assessment of potential risk from drug-drug interactions.During his time in the industry Dr Best has expanded the utilisation of mass spectrometry (specifically triple quadrupole LC-MS/MS) to help solve drug discovery project challenges with a strong focus on maximizing data capture from in vivo samples, refining experimental designs to permit better PD endpoints and expanding LC-MS/MS support for biological screening assays, where a mass spectrometry end-point is required, for the measurement of more challenging endogenous analytes.</blockquote></div>

More from less: LC-MS/MS an Enabling Technology to Maximize Bioanalytical Data Collection from Small Sample Volumes

An overview of analytical approaches in Discovery Bioanalysis CNS measurement, to deliver more information from lower sample volume.

LC-MS/MS to Maximize Bioanalytical Data Collection

<div><div><div>MALDI MS is ideally suited to increase productivity with rapid automated measurements. They provide near instant mass verification and information about impurities and degradants, which is valuable in quality control, assay optimization, and verification of substrates. Learn how the novel neofleX™ MALDI-TOF/TOF system&nbsp;enhances these workflows.</div></div></div><div><div><div><h5>Key Learning Objectives:</h5><ul><li>Overview of neofleX™ technology and its benefits to life sciences applications</li><li>Rapid automated analysis of a wide range of analytes including oligonucleotides and peptides</li><li>Software solutions for batch mode post-processing of automated runs</li></ul></div></div></div><div><div><div><h5>Who Should Attend:</h5><ul><li>Characterization team leaders in biopharma companies and CROs</li><li>Mass spectrometry core lab managers</li><li>Anyone who is interested in rapid automated MS analysis</li><li>Researchers who would like to learn about the latest MALDI-TOF/TOF technology</li><li>Anyone who is interested in oligonucleotide and peptide analysis</li></ul><div><div><div><div><blockquote><div>Presenter: Sergei Dikler, Ph.D. (Senior Market Manager, MALDI Technologies, Bruker Scientific LLC, Billerica, MA, USA)Sergei Dikler, Ph.D., is a Senior Market Manager focused on promoting MALDI technologies. Dr. Dikler received his Ph.D. degree at Texas A&amp;M University. He is an expert in MALDI application development and high-throughput MSPresenter: Sinduri Vuppala, Ph.D. (Field Applications Specialist, Bruker Scientific LLC, Billerica, MA, USA)Sinduri Vuppala, Ph.D., is a Field Applications Specialist for non-imaging MALDI applications at Bruker. Dr. Vuppala received her Ph.D., in Analytical Chemistry at the University of South Florida with focus on method development involving MALDI and CCS technologies.</div></blockquote></div></div></div></div></div></div></div>

Bruker: Rapid automated analysis using the novel neofleX™ platform

Rapid automated analysis using the novel neofleX™ platform

MALDI MS is ideally suited to increase productivity with rapid automated measurements. 

Biotherapeutics offer targeted therapies for treating a wide range of diseases with greater specificity and efficacy. However, unlike traditional small-molecule drugs, biotherapeutics are typically larger and more complex, requiring advanced techniques for their production, purification, and characterization.Therapeutic proteins, first introduced many years ago, have continually advanced in complexity. Since the introduction of monoclonal antibodies, we now have antibody drug conjugates, bispecific antibodies, fragments and fusion proteins, all of which are in various stages of development.&nbsp;To keep pace with biotherapeutics advances, analytical techniques must also advance.&nbsp;<h5>In this webinar, we will present chromatography findings on:</h5><ul><li>New workflows for intact and peptide mapping characterization of proteins</li><li>Advanced column chemistries for charge variant analysis with pH and salt gradients&nbsp;</li><li>Rapid desalting SEC column for high throughput analysis, ADC analysis with HIC and reversed phase chemistries</li><li>New digestion workflows coupled to a new peptide mapping column for sequence verification and post translation modification analysis</li></ul>This live webinar will be an excellent opportunity to boost your R&amp;D capabilities and strengthen your QC analytical methods for the characterization of biotherapeutics and gene therapies. Dr. Ken Cook will be presenting and answering your questions live.With over 20 years of innovation, Thermo Fisher Scientific is a leader in biomolecule separation and characterization, supported by a wealth of published research.Who should attend?&nbsp;<ul><li>Pharmaceutical and Biotech Researchers: Researchers involved in the development and characterization of biotherapeutics and gene therapies, including those working with therapeutic proteins.</li><li>Quality Control (QC) Analysts: Analysts responsible for ensuring the quality and consistency of biotherapeutic products, who will benefit from advanced methods in characterization and validation.</li><li>&nbsp;R&amp;D Managers: Managers who oversee research and development teams working with biotherapeutics, looking to enhance their workflows and methodologies.</li></ul><blockquote>Presenter: Dr. Ken Cook (Application Scientists Manager, Thermo Fisher Scientific)Dr. Ken Cook began his career in academia as a Biochemistry lecturer focused on protein chemistry and metabolism. With over 30 years of industry experience at Dionex, and later Thermo Fisher Scientific, his vast knowledge supporting and developing solutions within chromatography has established him as a bio-separations expert.Currently, Dr. Cook focuses on supporting and developing solutions for bio-pharmaceutical applications, particularly in the characterization of protein and oligonucleotide-based biotherapeutics. His work involves ongoing collaborations with both the biopharmaceutical industry and academic institutions.His expertise includes peptide mapping using LC/HRMS, charged variant analysis with novel MS coupling, glycan analysis, aggregate analysis, and on-line process monitoring. He also has a growing interest and notable success in gene therapy characterization.Given his immense experience, it is an honour to have Dr Cook share his knowledge.</blockquote>

Thermo Fisher Scientific: Innovations in Protein Characterization

Innovations in Protein Characterization

Boost your R&D capabilities and strengthen your QC analytical methods for the characterization of biotherapeutics and gene therapies.

LCMS webináře se zaměřením na LC/MS/MS - strana 41